Clinical Trial

Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Safety, tolerability, and biodistribution characteristics of 68Ga-XT771 will also be assessed.
Trial Details
NCT Number NCT07067905
Lead Sponsor Chinese PLA General Hospital
Collaborators: Sinotau Pharmaceutical Group
Conditions Clear Cell Renal Cell Carcinoma and Glioblastoma
Enrollment 15 participants
Start Date 2025-06-27
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-16